|
|||||
|
Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter |
Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
CTLT | Flynn Karen | Chief Commercial Officer | Jan 10 | Sale | 116.64 | 2,472 | 288,334 | 33,223 | Jan 11 06:54 PM |
CTLT | Flynn Karen | Pres. Biologics & CCO | Jan 11 | Sale | 112.30 | 2,478 | 278,279 | 34,544 | Jan 11 07:12 PM |
CTLT | Flynn Karen | Pres. Biologics & CCO | Jan 04 | Sale | 104.42 | 99 | 10,338 | 37,022 | Jan 05 09:44 PM |
WST | Flynn Karen | Sr VP & Chief Commercial Offic | Aug 07 | Option Exercise | 23.33 | 20,458 | 477,294 | 42,051 | Aug 09 10:59 AM |
WST | Flynn Karen | Sr VP & Chief Commercial Offic | Aug 07 | Sale | 116.23 | 20,458 | 2,377,833 | 21,593 | Aug 09 10:59 AM |
WST | Flynn Karen | Sr VP & Chief Commercial Offic | Sep 06 | Sale | 83.28 | 14,581 | 1,214,306 | 13,513 | Sep 07 09:40 AM |
WST | Flynn Karen | President, Pharma Pckg Systems | Nov 10 | Option Exercise | 20.91 | 18,020 | 376,713 | 42,630 | Nov 12 12:39 PM |
WST | Flynn Karen | President, Pharma Pckg Systems | Nov 10 | Sale | 63.03 | 18,020 | 1,135,723 | 24,610 | Nov 12 12:39 PM |
WST | Flynn Karen | President, Pharma Pckg Systems | May 22 | Option Exercise | 16.05 | 3,091 | 49,595 | 27,701 | May 26 09:51 AM |
WST | Flynn Karen | President, Pharma Pckg Systems | May 22 | Sale | 55.24 | 3,091 | 170,737 | 24,610 | May 26 09:51 AM |
WST | Flynn Karen | President, Pharma Pckg Systems | May 18 | Option Exercise | 16.05 | 1,909 | 30,630 | 26,519 | May 19 10:08 AM |
WST | Flynn Karen | President, Pharma Pckg Systems | May 18 | Sale | 55.00 | 1,909 | 104,995 | 24,610 | May 19 10:08 AM |
WST | Flynn Karen | President, America's Region | Nov 19 | Option Exercise | 22.89 | 5,500 | 125,895 | 16,036 | Nov 19 03:35 PM |
WST | Flynn Karen | President, America's Region | Nov 19 | Sale | 47.75 | 5,500 | 262,625 | 10,536 | Nov 19 03:35 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite